BAHA Advisory · U.S. Market Entry

Who this is for

Who we work with.

We work with

✓International healthtech, medtech & digital healthGlobally, including Europe, Asia, South America.

✓Validated and generating traction at homeA real product with real customers, not a concept looking for a market.

✓Ready to build a real U.S. operating entityBoots on the ground and a genuine operating business, not a paper entity with a nominal “US lead.”

Not a fit yet

×Still proving the product at homeIf home-market traction isn’t there yet, the U.S. isn’t the next step.

×Planning a paper entity onlyA Delaware entity with a nominal U.S. lead doesn’t unlock capital or contracts.

Fit gets settled honestly in the diagnostic, go, not yet, or not this way.

A structured, phased journey, not open-ended consulting.

Four phases, in order. Each one has a defined job and a defined way out.

Diagnose

The US Readiness Diagnostic, a complete, honest assessment of where you stand across product, evidence, leadership, GTM, operations, and capital.

You getA readiness scorecard plus a candid verdict. The way outGo, not yet, or not this way.

Architect

We design your U.S. entry, entity structure, the U.S. leadership you need, your commercial model, and your market positioning, and activate the right partners to execute.

You getYour U.S. entry, designed, and the specialists to build it, including regulatory and clinical partners. The way outA genuine U.S. presence strategy taking shape.

Execute & Course-Correct

We stay alongside you as you hire, sell, and talk to investors, adjusting as the market teaches you what’s working.

You getAdvice at every decision that matters. The way outA U.S. business that’s learning and correcting in real time.

Scale Advisory

An ongoing advisory relationship for companies that have made the leap and want a senior lens as they grow, sometimes formalized as a seat on your advisory board or your board of directors, so the validation that got you here stays with you.

You getA senior advisor who already knows your strategy and positioning. The way inOptional, if a senior advisor is required during your growth mode.

The keystone

One move unlocks everything you came for.

Becoming genuinely US-ready isn’t bureaucracy, it’s the single structural move the rest depends on.

The move

A real U.S. entity, led by US-based leadership with genuine ownership in the business.

US citizens or permanent residents, holding real equity, a real extension of your founding team. Not a paper entity with a nominal “US lead.”

01Eligible for U.S. non-dilutive capital.Grants and foundation and government funding increasingly require US-based ownership and leadership.

02Fundable by U.S. venture.Most U.S. VCs have mandates that limit or prevent investing in non-U.S. entities. Real U.S. presence is what puts you on the table.

03Able to win U.S. contracts.Many hospitals, payers, and enterprises won’t take on the compliance and legal burden of contracting with a company that lacks genuine U.S. presence.

The same thing that makes you fundable makes you sellable.

Advisory vs. execution

We design it. Specialists execute it. We make it fit.

We design what your U.S. entry requires, and that design is what tells you which specialists you actually need. We coordinate a curated ecosystem of healthcare-versed partners who execute that specialized work; you contract directly with each one, and we make sure it all fits together.

Legal

Padilla Law ↗

Healthcare-versed, cross-jurisdiction U.S. entity formation, runs the Delaware flip properly.

Talent

MDisrupt ↗

The people you need in the U.S.: healthcare leadership, commercial teams and advisors, fractional or full-time.

Banking

Silicon Valley Bank ↗

Banking and cross-border operational relationships.

Regulatory & clinical

RCI Global Partners ↗

FDA regulatory strategy and submissions, clinical evidence, and market access for MedTech, biotech and pharma.

Clinical voice

KOLs & SMEs

Clinicians and healthcare subject-matter experts from the BAHA bench and HIP.fund network, sharpening your positioning per engagement.

BAHA stays purely advisory. We’re never inside the execution contract. One coherent healthcare strategy, the right specialists, without assembling them yourself.

The HIP.fund relationship

Related to HIP.fund, and what that means for you.

HIP.fund ↗

BAHA Advisory and HIP.fund are related entities built on the same foundation. As an active healthcare investor, BAHA brings a clear-eyed view of what U.S. venture actually funds, and genuine U.S. readiness is what makes a company fundable by U.S. venture in the first place. Most U.S. VCs, HIP.fund included, can only invest in U.S. entities.

The readiness work itself is what opens that door: once it’s complete, you’re positioned to approach U.S. investors, HIP.fund included, and you’ll be evaluated on the same basis as any other company it considers. Your advisory engagement stands on its own; investing is a separate decision, made separately.

What success looks like

A U.S. business that’s real.

Presence

Genuine U.S. presence that unlocks capital and contracts.

The keystone in place: entity, leadership, ownership, and the doors it opens, opening.

Avoided cost

The seven-figure wrong turn, not taken.

The mis-hires, wrong segments, and dead-end pilots that consume 12–24 months, skipped.

Leadership

A U.S. leader who’s a real extension of the founding team.

On the cap table, in the room, carrying the mission, not a nominal title.

Client story

Xploro, in detail.

U.S. Market Entry · UK health tech ·

Validated in the UK. Not yet U.S.-ready.

ChallengeA UK company with a strong product and real traction at home, facing the hardest test in the industry: building a real, credible presence in the U.S. market.

ApproachStrategic advisor and close confidant to the founder-CEO for nearly three years, engaged directly in the decisions that would define the company’s U.S. trajectory.

SolutionSharpened the value proposition and positioning for U.S. prospects, with direct work on client management, investor strategy, and board dynamics as the company scaled stateside.

The advisory partThe center of gravity: building a UK company that could sell, raise capital, and operate like a true U.S. player.

Result

An operating U.S. business: capital raised, contracts won, and a founder equipped to make the right calls.

Samir is one of a kind. Six years on, we’re still meeting every couple of weeks. As the founder of a UK startup, he’s helped me navigate the complexities of the US healthcare market. Appoint him as a board member, engage him as an advisor or pitch him for investment – whichever, Samir is your man

Dom Raban
CEO and Co-founder, Xploro

The team

Operators who have worked beyond the U.S.

Samir Batra

Founder & Managing Partner · 25 years, operator, advisor and active investor · has lived and worked in Asia, Europe, South America and the U.S.

Joe Badalian

Advisor · 23 years, hospital and health system CEO, COO and EVP, M&A and turnarounds

Margit Chapman

Advisor · 50+ years, oncology nurse turned health IT leader, clinical strategy and value-based care

Amit Malhotra

Advisor · 18 years, operator across healthcare, product, technology and AI transformation

Nick Scharlatt

Advisor · 25 years, health IT co-founder, building sales, marketing and operations from the ground up

U.S. operators with international relationships.

BAHA is a senior advisory team, backed by advisors with deep international relationships and accelerator experience. We bring those relationships to your engagement as your U.S. entry requires them.

International relationships Accelerator experience U.S. operators KOLs & SMEs

Fair questions.

Isn’t a Delaware entity enough? +

No. A paper entity with a nominal “US lead” is the most common mistake we see. What works is genuine U.S. presence: U.S.-based leadership with real equity ownership, a real extension of your founding team.

What exactly is the diagnostic? +

A defined first step: an honest readiness assessment across product, evidence, leadership, GTM, operations, and capital, delivered as a readiness scorecard and a candid verdict on whether, and how, to make the move.

Will you actually tell me not to enter? +

Yes. Go, not yet, or not this way: the verdict is real, even when it costs us the downstream engagement. That independence is the point.

Do you execute, or just advise? +

We advise and coordinate. A curated partner ecosystem (legal, talent, banking, clinical) executes the specialized work, and you contract with each specialist directly. We make it all fit together.

How does the HIP.fund relationship work? +

They’re related entities, kept separate. What the work actually does: genuine U.S. readiness makes you eligible for U.S. venture at all. Most U.S. funds, HIP.fund included, can only invest in U.S. entities. Once you’re there, you can pitch any of them. If that includes HIP.fund, you’re evaluated the same way as every other company it sees.

Do you only work with European companies? +

No. We work globally, including Europe, Asia and South America. The common thread isn’t geography; it’s being validated at home and serious about the U.S.

The first call

Bring your US plan.

Bring your US plan, the real one, not the polished version. In 45 minutes, we’ll name the one thing most likely to cost you time and money, and what to do about it. In writing, within 48 hours.

This isn’t a sales call. It’s not a pitch. We’re not going to tell you to “just enter.” We’ll tell you what we actually see.

What we’ll cover

Real questions past sessions have started with.

We flipped to Delaware eighteen months ago and nothing changed. What did we miss?
US VCs keep saying “come back when you have US presence.” What do they actually mean by that?
We hired a “US lead” with a title but no equity, and nothing has opened up because of it.
Our evidence and case studies are strong at home, but US buyers don’t seem to care.
Everyone tells us to “just enter.” No one tells us what could actually go wrong.
We have limited runway left for a US push. How do we know if we’re ready before we spend it?

Rough is fine. Sharpening it into the real question is our job, not yours.

Before we talk We read what you send us, and your site. We show up with a view already formed, not a blank page, at whatever hour works on your side of the world.

What you keep A one-page written summary naming the blind spot and the first move to close it, within 48 hours.

How it ends With the blind spot named, not a proposal. The US Readiness Diagnostic is already on this site if you want to look at it yourselves. If working together makes sense after that, let’s talk.

This call finds one likely blind spot. The Diagnostic covers all six areas, and comes later, if we end up working together.

Pick a time 45 min · Zoom · With Samir